<DOC>
	<DOCNO>NCT00324129</DOCNO>
	<brief_summary>In study , MGCD0103 , new anticancer drug investigation , give three time weekly patient leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>A Phase I Study MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes</brief_title>
	<detailed_description>Phase I dose escalate study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Patients must diagnosis one following : relapsed refractory AML ALL fail respond standard therapy , progress despite standard therapy relapse refractory Myelodysplastic Syndromes previously untreated AML Myelodysplastic Syndromes patient &gt; 60 year age refuse candidate induction chemotherapy Patients relapse refractory CML fail respond Imatinib therapy standard therapy , progress despite standard therapy , standard therapy exist ECOG performance status 0 , 1 , 2 Age â‰¥ 18 year Patients legal representative must able read , understand , sign write informed consent ( approved IRB/EC ) prior study entry Patients history another cancer basal cell carcinoma cervical intraepithelial neoplasia Pregnant lactate woman Patients partner , either childbearing potential , use adequate birth control measure throughout study 90 day follow last dose study medication Patients know meningeal metastasis ( es ) Patients active uncontrolled infection , fever &gt; 38.5 C Patients serious illness , medical condition , medical history , would likely interfere patient 's participation study Patients treat investigational drug anticancer therapy within 30 day study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Phase I</keyword>
</DOC>